Met Life Investment Management, LLC Allakos Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

36 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 09, 2024
BUY
$2.13 - $5.55 $75,137 - $195,781
35,276 New
35,276 $80,000
Q2 2023

Apr 29, 2024
BUY
$3.6 - $5.25 $126,993 - $185,199
35,276 New
35,276 $153,000
Q2 2023

Aug 10, 2023
BUY
$3.6 - $5.25 $126,993 - $185,199
35,276 New
35,276 $153,000
Q1 2022

May 12, 2022
SELL
$5.08 - $9.81 $63,794 - $123,193
-12,558 Closed
0 $0
Q4 2021

Jun 21, 2023
BUY
$8.55 - $111.89 $107,370 - $1.41 Million
12,558 New
12,558 $122,000
Q3 2021

Jun 21, 2023
BUY
$76.53 - $110.43 $961,063 - $1.39 Million
12,558 New
12,558 $1.33 Million
Q2 2021

May 17, 2024
BUY
$85.37 - $114.1 $170,654 - $228,085
1,999 Added 18.93%
12,558 $1.07 Million
Q2 2021

Jun 21, 2023
BUY
$85.37 - $114.1 $1.07 Million - $1.43 Million
12,558 New
12,558 $1.07 Million
Q2 2021

Mar 22, 2023
BUY
$85.37 - $114.1 $170,654 - $228,085
1,999 Added 18.93%
12,558 $1.07 Million
Q2 2021

Aug 16, 2021
BUY
$85.37 - $114.1 $170,654 - $228,085
1,999 Added 18.93%
12,558 $1.07 Million
Q1 2021

May 17, 2024
BUY
$109.73 - $153.66 $1.16 Million - $1.62 Million
10,559 New
10,559 $1.21 Million
Q1 2021

Jun 26, 2023
BUY
$109.73 - $153.66 $1.16 Million - $1.62 Million
10,559 New
10,559 $1.21 Billion
Q4 2020

May 24, 2024
SELL
$79.58 - $152.45 $22,282 - $42,686
-280 Reduced 2.58%
10,559 $1.48 Million
Q4 2020

Jun 22, 2023
BUY
$79.58 - $152.45 $840,285 - $1.61 Million
10,559 New
10,559 $1.48 Million
Q4 2020

Mar 22, 2023
SELL
$79.58 - $152.45 $22,282 - $42,686
-280 Reduced 2.58%
10,559 $1.48 Million
Q4 2020

Feb 16, 2021
SELL
$79.58 - $152.45 $22,282 - $42,686
-280 Reduced 2.58%
10,559 $1.48 Million
Q3 2020

Jun 26, 2023
BUY
$66.43 - $90.99 $720,034 - $986,240
10,839 New
10,839 $882,000
Q2 2020

May 24, 2024
BUY
$44.04 - $80.69 $477,349 - $874,598
10,839 New
10,839 $779 Million
Q2 2020

Jun 26, 2023
BUY
$44.04 - $80.69 $477,349 - $874,598
10,839 New
10,839 $778,000
Q2 2020

Mar 22, 2023
BUY
$44.04 - $80.69 $115,076 - $210,842
2,613 Added 31.77%
10,839 $778,000
Q2 2020

Aug 14, 2020
BUY
$44.04 - $80.69 $115,076 - $210,842
2,613 Added 31.77%
10,839 $779,000
Q1 2020

Jul 12, 2023
BUY
$44.49 - $93.39 $365,974 - $768,226
8,226 New
8,226 $365,000
Q4 2019

Jul 12, 2023
BUY
$66.49 - $137.73 $546,946 - $1.13 Million
8,226 New
8,226 $784,000
Q3 2019

Jul 12, 2023
BUY
$31.0 - $89.73 $255,006 - $738,118
8,226 New
8,226 $646,000
Q3 2019

Mar 22, 2023
BUY
$31.0 - $89.73 $43,648 - $126,339
1,408 Added 20.65%
8,226 $646,000
Q3 2019

Nov 14, 2019
BUY
$31.0 - $89.73 $43,648 - $126,339
1,408 Added 20.65%
8,226 $647,000
Q2 2019

Jul 12, 2023
BUY
$36.0 - $44.73 $296,136 - $367,948
8,226 New
8,226 $356,000
Q1 2019

Jul 13, 2023
BUY
$33.79 - $51.99 $230,380 - $354,467
6,818 New
6,818 $276,000
Q1 2019

Mar 22, 2023
BUY
$33.79 - $51.99 $93,801 - $144,324
2,776 Added 68.68%
6,818 $276,000
Q1 2019

May 15, 2019
BUY
$33.79 - $51.99 $93,801 - $144,324
2,776 Added 68.68%
6,818 $276,000
Q4 2018

Jul 13, 2023
BUY
$31.59 - $62.65 $127,686 - $253,231
4,042 New
4,042 $211,000
Q4 2018

Mar 22, 2023
SELL
$31.59 - $62.65 $176,935 - $350,902
-5,601 Reduced 58.08%
4,042 $211,000
Q4 2018

Feb 14, 2019
SELL
$31.59 - $62.65 $176,935 - $350,902
-5,601 Reduced 58.08%
4,042 $211,000
Q3 2018

Jul 13, 2023
BUY
$31.25 - $47.64 $192,468 - $293,414
6,159 New
6,159 $277,000
Q3 2018

Mar 22, 2023
BUY
$31.25 - $47.64 $301,343 - $459,392
9,643 New
9,643 $433,000
Q3 2018

Nov 14, 2018
BUY
$31.25 - $47.64 $301,343 - $459,392
9,643 New
9,643 $434,000

Others Institutions Holding ALLK

# of Institutions
82
Shares Held
64.7M
Call Options Held
47.1K
Put Options Held
1K
View Full List

About Allakos Inc.

ALLK Quotes by TradingView
  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $81.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email